Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan-Feb;28(1):e145-e147.
doi: 10.1097/MJT.0000000000000946.

Golimumab-Associated Glomerulonephritis

Affiliations

Golimumab-Associated Glomerulonephritis

Nikhil Agrawal et al. Am J Ther. 2021 Jan-Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

References

    1. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–245.
    1. Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis. 2009;68:789–796.
    1. Keystone EC, Genovese MC, Hall S, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: results through 2 years of the GO-FORWARD study extension. J Rheumatol. 2013;40:1097–1103.
    1. Saka Y, Taniguchi Y, Nagahara Y, et al. Rapidly progressive lupus nephritis associated with golimumab in a patient with systemic lupus erythematosus and rheumatoid arthritis. Lupus. 2017;26:447–448.
    1. Pàmies A, Castro S, Poveda MJ, et al. Leucocytoclastic vasculitis associated with golimumab. Rheumatology (Oxford). 2013;52:1921–1923.

MeSH terms

LinkOut - more resources